武田-话题@MedSci

#武田#

91篇内容 | 1417人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2106186, encodeId=cf8221061862d, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a><a href='/topic/show?id=85dc4340cd' target=_blank style='color:#2F92EE;'>#CD47单抗#</a><a href='/topic/show?id=c94a1050e951' target=_blank style='color:#2F92EE;'>#Magrolimab#</a>为基础的三联治疗在<a href='/topic/show?id=11fe2435ff' target=_blank style='color:#2F92EE;'>#AML#</a>中取得显著突破, objectTitle=ASH 2022：武田CD47单抗Magrolimab为基础的三联治疗在AML中取得显著突破, objectType=article, longId=751774, objectId=3e09e5177482, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20221123/31323a17ac4d4b7494651c06a4fd8df8.jpg, objectUrl=/article/show_article.do?id=3e09e5177482, replyNumber=0, likeNumber=64, createdTime=2022-12-15, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=3e09e5177482, moduleTitle=ASH 2022：武田CD47单抗Magrolimab为基础的三联治疗在AML中取得显著突破, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e09e5177482)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=1517292, encodeId=9d23151e2922d, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田的QDENGA®▼（登革热四价疫苗[减毒活疫苗]）在印度尼西亚获准使用，无论是否有登革热暴露史均可使用, objectType=article, longId=737025, objectId=6c98e37025e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c98e37025e6, replyNumber=0, likeNumber=56, createdTime=2022-08-27, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c98e37025e6, moduleTitle=武田的QDENGA®▼（登革热四价疫苗[减毒活疫苗]）在印度尼西亚获准使用，无论是否有登革热暴露史均可使用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6c98e37025e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517291, encodeId=1591151e29191, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田发布评估HYQVIA®用于慢性炎性脱髓鞘性多发性神经根神经病(CIDP)维持治疗的枢纽性3期临床试验阳性顶线结果, objectType=article, longId=733249, objectId=a155e3324911, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a155e3324911, replyNumber=0, likeNumber=53, createdTime=2022-07-27, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a155e3324911, moduleTitle=武田发布评估HYQVIA®用于慢性炎性脱髓鞘性多发性神经根神经病(CIDP)维持治疗的枢纽性3期临床试验阳性顶线结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a155e3324911)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517290, encodeId=5dd3151e2905b, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=预防登革热枢纽性临床试验显示，武田的登革热候选疫苗可提供持续4.5年的保护力, objectType=article, longId=729130, objectId=308be2913085, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=308be2913085, replyNumber=0, likeNumber=56, createdTime=2022-06-12, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=308be2913085, moduleTitle=预防登革热枢纽性临床试验显示，武田的登革热候选疫苗可提供持续4.5年的保护力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=308be2913085)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517289, encodeId=3443151e28913, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田在ASCO和EHA上展示肿瘤学产品组合和研发产品线的最新研究成果, objectType=article, longId=728477, objectId=a6b9e2847722, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a6b9e2847722, replyNumber=0, likeNumber=43, createdTime=2022-06-03, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a6b9e2847722, moduleTitle=武田在ASCO和EHA上展示肿瘤学产品组合和研发产品线的最新研究成果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a6b9e2847722)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517288, encodeId=b088151e28812, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田和Seagen呈报的ADCETRIS®联合用药数据显示，晚期霍奇金淋巴瘤患者的总生存(OS)改善有统计学意义, objectType=article, longId=728253, objectId=2392e28253a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2392e28253a7, replyNumber=0, likeNumber=49, createdTime=2022-06-01, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2392e28253a7, moduleTitle=武田和Seagen呈报的ADCETRIS®联合用药数据显示，晚期霍奇金淋巴瘤患者的总生存(OS)改善有统计学意义, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2392e28253a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517287, encodeId=d219151e2876a, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田宣布Nuvaxovid®新冠疫苗在日本获批用于初次和加强免疫接种, objectType=article, longId=724609, objectId=a2c0e2460940, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2c0e2460940, replyNumber=0, likeNumber=52, createdTime=2022-04-21, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2c0e2460940, moduleTitle=武田宣布Nuvaxovid®新冠疫苗在日本获批用于初次和加强免疫接种, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a2c0e2460940)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517286, encodeId=141e151e28682, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田的Exkivity (mobocertinib) 获得英国MHRA有条件上市许可，用于治疗罕见非小细胞肺癌, objectType=article, longId=301596, objectId=a1cb301596e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a1cb301596e2, replyNumber=0, likeNumber=35, createdTime=2022-03-26, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a1cb301596e2, moduleTitle=武田的Exkivity (mobocertinib) 获得英国MHRA有条件上市许可，用于治疗罕见非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a1cb301596e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517285, encodeId=245a151e285ef, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田制药取得强劲的2021财年第三季度业绩，调高全年预测，以反映强劲发展势头, objectType=article, longId=295366, objectId=43d6295366c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43d6295366c1, replyNumber=0, likeNumber=36, createdTime=2022-02-11, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43d6295366c1, moduleTitle=武田制药取得强劲的2021财年第三季度业绩，调高全年预测，以反映强劲发展势头, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=43d6295366c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517284, encodeId=36dc151e284f9, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田收购Adaptate Biotherapeutics，以开发针对实体瘤的新型Gamma Delta (γδ) T细胞衔接器疗法, objectType=article, longId=294032, objectId=36af294032f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36af294032f6, replyNumber=0, likeNumber=42, createdTime=2022-01-17, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36af294032f6, moduleTitle=武田收购Adaptate Biotherapeutics，以开发针对实体瘤的新型Gamma Delta (γδ) T细胞衔接器疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36af294032f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517283, encodeId=8473151e283d3, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田收到美国FDA对TAK-721的完整回应函, objectType=article, longId=292559, objectId=c5c1292559ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c5c1292559ff, replyNumber=0, likeNumber=56, createdTime=2021-12-24, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c5c1292559ff, moduleTitle=武田收到美国FDA对TAK-721的完整回应函, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c5c1292559ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517282, encodeId=0895151e28247, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田在美国血液学会(ASH)第63届年会上发布可促进血液病和肿瘤患者治疗的新研究成果, objectType=article, longId=221842, objectId=bf7022184289, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf7022184289, replyNumber=0, likeNumber=51, createdTime=2021-12-12, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf7022184289, moduleTitle=武田在美国血液学会(ASH)第63届年会上发布可促进血液病和肿瘤患者治疗的新研究成果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf7022184289)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517281, encodeId=7aec151e281ac, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田将收购GammaDelta Therapeutics，以加速开发针对实体瘤的异体γδT细胞疗法, objectType=article, longId=219603, objectId=6d1621960324, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d1621960324, replyNumber=0, likeNumber=49, createdTime=2021-11-03, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d1621960324, moduleTitle=武田将收购GammaDelta Therapeutics，以加速开发针对实体瘤的异体γδT细胞疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6d1621960324)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517280, encodeId=2f66151e28072, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田与JCR Pharmaceuticals合作，将亨特综合征下一代治疗药物商业化, objectType=article, longId=218421, objectId=20732184217a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20732184217a, replyNumber=0, likeNumber=39, createdTime=2021-10-13, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20732184217a, moduleTitle=武田与JCR Pharmaceuticals合作，将亨特综合征下一代治疗药物商业化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=20732184217a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517279, encodeId=6b67151e2791d, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田的EXKIVITY™ (mobocertinib)成为美国FDA首次核准的专为EGFR外显子20插入+ NSCLC患者设计的口服治疗药物, objectType=article, longId=217428, objectId=aa6621e428d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa6621e428d6, replyNumber=0, likeNumber=44, createdTime=2021-09-24, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa6621e428d6, moduleTitle=武田的EXKIVITY™ (mobocertinib)成为美国FDA首次核准的专为EGFR外显子20插入+ NSCLC患者设计的口服治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa6621e428d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517278, encodeId=7e37151e2789c, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田发布PANTHER 3期(Pevonedistat-3001)试验的全新消息, objectType=article, longId=216657, objectId=d3c021665e68, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3c021665e68, replyNumber=0, likeNumber=43, createdTime=2021-09-05, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3c021665e68, moduleTitle=武田发布PANTHER 3期(Pevonedistat-3001)试验的全新消息, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3c021665e68)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517277, encodeId=3237151e2770a, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田和Frazier Healthcare Partners宣布合作成立HilleVax, Inc.以开发临床阶段诺如病毒候选疫苗, objectType=article, longId=215179, objectId=45d52151e9f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=45d52151e9f8, replyNumber=0, likeNumber=63, createdTime=2021-08-04, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=45d52151e9f8, moduleTitle=武田和Frazier Healthcare Partners宣布合作成立HilleVax, Inc.以开发临床阶段诺如病毒候选疫苗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=45d52151e9f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517275, encodeId=66c2151e27505, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=长期安全性和有效性结果凸显武田登革热候选疫苗的潜在影响力, objectType=article, longId=211814, objectId=fe53211814ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe53211814ff, replyNumber=0, likeNumber=39, createdTime=2021-05-27, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe53211814ff, moduleTitle=长期安全性和有效性结果凸显武田登革热候选疫苗的潜在影响力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe53211814ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517274, encodeId=8b2c151e274fe, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田制药将呈报ICLUSIG® (ponatinib) 2期OPTIC试验主要分析的阳性结果，加强填补慢性期CML治疗空白的能力, objectType=article, longId=211778, objectId=aba2211e7815, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aba2211e7815, replyNumber=0, likeNumber=47, createdTime=2021-05-26, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aba2211e7815, moduleTitle=武田制药将呈报ICLUSIG® (ponatinib) 2期OPTIC试验主要分析的阳性结果，加强填补慢性期CML治疗空白的能力, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aba2211e7815)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1517276, encodeId=9e51151e2765e, content=<a href='/topic/show?id=a0176333892' target=_blank style='color:#2F92EE;'>#武田#</a>, objectTitle=武田呈报mobocertinib的全新结果，进一步证实EGFR外显子20插入+ mNSCLC患者的临床收益, objectType=article, longId=211619, objectId=39722116191a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39722116191a, replyNumber=0, likeNumber=48, createdTime=2021-05-23, rootId=0, userName=12498f17m69暂无昵称, userId=f6da11069119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39722116191a, moduleTitle=武田呈报mobocertinib的全新结果，进一步证实EGFR外显子20插入+ mNSCLC患者的临床收益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39722116191a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

武田

2020-05-29

(审核中...)

前往app查看评论内容

#武田##CD47单抗##Magrolimab#为基础的三联治疗在#AML#中取得显著突破

ASH 2022：武田CD47单抗Magrolimab为基础的三联治疗在AML中取得显著突破

2022-12-15发表于上海

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田的QDENGA®▼（登革热四价疫苗[减毒活疫苗]）在印度尼西亚获准使用，无论是否有登革热暴露史均可使用

2022-08-27

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田发布评估HYQVIA®用于慢性炎性脱髓鞘性多发性神经根神经病(CIDP)维持治疗的枢纽性3期临床试验阳性顶线结果

2022-07-27

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

预防登革热枢纽性临床试验显示，武田的登革热候选疫苗可提供持续4.5年的保护力

2022-06-12

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田在ASCO和EHA上展示肿瘤学产品组合和研发产品线的最新研究成果

2022-06-03

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田和Seagen呈报的ADCETRIS®联合用药数据显示，晚期霍奇金淋巴瘤患者的总生存(OS)改善有统计学意义

2022-06-01

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田宣布Nuvaxovid®新冠疫苗在日本获批用于初次和加强免疫接种

2022-04-21

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田的Exkivity (mobocertinib) 获得英国MHRA有条件上市许可，用于治疗罕见非小细胞肺癌

2022-03-26

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田制药取得强劲的2021财年第三季度业绩，调高全年预测，以反映强劲发展势头

2022-02-11

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田收购Adaptate Biotherapeutics，以开发针对实体瘤的新型Gamma Delta (γδ) T细胞衔接器疗法

2022-01-17

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田收到美国FDA对TAK-721的完整回应函

2021-12-24

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田在美国血液学会(ASH)第63届年会上发布可促进血液病和肿瘤患者治疗的新研究成果

2021-12-12

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田将收购GammaDelta Therapeutics，以加速开发针对实体瘤的异体γδT细胞疗法

2021-11-03

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田与JCR Pharmaceuticals合作，将亨特综合征下一代治疗药物商业化

2021-10-13

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田的EXKIVITY™ (mobocertinib)成为美国FDA首次核准的专为EGFR外显子20插入+ NSCLC患者设计的口服治疗药物

2021-09-24

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田发布PANTHER 3期(Pevonedistat-3001)试验的全新消息

2021-09-05

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田和Frazier Healthcare Partners宣布合作成立HilleVax, Inc.以开发临床阶段诺如病毒候选疫苗

2021-08-04

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

长期安全性和有效性结果凸显武田登革热候选疫苗的潜在影响力

2021-05-27

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田制药将呈报ICLUSIG® (ponatinib) 2期OPTIC试验主要分析的阳性结果，加强填补慢性期CML治疗空白的能力

2021-05-26

12498f17m69暂无昵称 (审核中...)

前往app查看评论内容

#武田#

武田呈报mobocertinib的全新结果，进一步证实EGFR外显子20插入+ mNSCLC患者的临床收益

2021-05-23

科室
- - 订阅+
  - 更多科室
工具
服务